表紙：RNA療法臨床試験市場- 成長、将来展望、競合分析、2023年～2031年

市場調査レポート

商品コード

1340134

RNA療法臨床試験市場- 成長、将来展望、競合分析、2023年～2031年

RNA Therapy Clinical Trials Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

出版日: 2023年07月27日
発行: Acute Market Reports
ページ情報: 英文 110 Pages
納期: 即日から翌営業日

価格

PDF (Single User License)

USD 4,500 648,270円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 6,500 936,390円

レポートPDFを10名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 9,000 1,296,540円

レポートPDFを企業内すべての方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

RNA療法臨床試験市場は、2023年から2031年の予測期間中、RNAベースの治療アプローチの進歩と、標的化治療および個別化治療の可能性により、CAGR 4%の成長が見込まれています。RNA療法は、リボ核酸（RNA）分子を用いて特定の遺伝子を標的とし、タンパク質の産生を調節するもので、がん、遺伝性疾患、感染症などさまざまな疾患の治療に有望な機会を提供します。より多くのRNAベースの治療法が臨床試験を経て商業化に向かうにつれ、市場の収益は上昇基調を続けると予想されます。これまで治療不可能だった疾患に対処できる可能性があり、個別化医療への需要が高まっていることも、市場の拡大に寄与しています。RNA治療分野で進行中の臨床試験は、こうした革新的な治療法の安全性と有効性を評価するために不可欠です。より多くの臨床データが入手可能になるにつれ、RNAベースの医薬品に対する規制当局の承認は増加し、臨床現場でのより広い採用への道が開かれると思われます。結論として、RNA療法臨床試験市場は、RNAベースの治療が疾病治療に革命をもたらし、ヘルスケアに個別化された標的アプローチを提供する可能性に後押しされ、目覚ましい収益成長と有望なCAGRを示しています。臨床試験が進み、より多くのRNAベースの医薬品が市場に参入するにつれて、RNA治療は将来の医療と患者ケアに大きな影響を与えるようになります。

RNA治療技術の進歩

RNA治療技術の進歩は、RNA療法臨床試験市場の成長を支える大きな要因となっています。脂質ナノ粒子やウイルスベクターなど、より安定的で効率的な送達システムの開発により、RNAベースの治療薬を標的組織や細胞に送達することが改善されました。さらに、RNA合成と修飾技術の革新により、RNA分子の安定性と特異性が向上し、病気の原因となる遺伝子をより効果的に標的にできるようになっています。このような技術の進歩は、RNA療法の潜在的な応用範囲を拡大し、幅広い疾患の治療への利用を模索する臨床試験の急増につながっています。Nature Communications誌に掲載された研究では、脂質ナノ粒子を用いたmRNA治療薬の送達の成功について報告され、前臨床モデルにおける安定性と治療効果の向上が示されました。Journal of Controlled Release』誌に掲載された別の研究では、自己増幅型mRNAをワクチン・プラットフォームとして使用することが強調され、動物モデルにおいて感染症に対する強固な免疫応答が示されました。これらの例は、RNA治療薬の技術的進歩がいかに臨床試験の進展を促し、治療成功の可能性を高めているかを示しています。

慢性疾患と遺伝性疾患の有病率の上昇

慢性疾患や遺伝性疾患の有病率の増加は、革新的で的を絞った治療に対する需要を煽り、RNA療法臨床試験の成長を促進しています。RNAベースの治療法は、特定の疾患原因遺伝子を標的とし、タンパク質産生を調節することにより、これまで治療不可能であった疾患に対処する可能性を提供します。がん、希少遺伝子疾患、神経変性疾患などの疾患が、RNAベースの治療薬の重要なターゲットとして浮上しています。これらの疾患に対する効果的な治療法の発見が急務となっているため、RNA療法の安全性と有効性を調査する臨床試験が急増しており、将来の医療介入の有望な手段として位置づけられています。米国がん協会は、がんが依然として世界の主要死因の一つであることを報告し、RNAベースのアプローチを含む標的療法を開発するための重要な研究開発と臨床努力を促しています。同様に、全米希少疾患機構（NORD）のような組織は、希少な遺伝性疾患に対する革新的な治療法の必要性を強調し、RNA療法臨床試験への関心と投資を高めています。

支持的な規制環境

RNAベースの治療法に対する支援的な規制環境は、臨床試験市場の成長を促進する上で重要な役割を果たしています。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、RNA療法の開発と承認を促進するためのフレームワークと迅速なパスウェイを確立しています。これらのパスウェイにより、有望なRNAベースの治療法の臨床開発と審査が加速され、これらの治療法の市場投入に要する時間とコストが削減されます。規制当局の支援は、より多くの製薬会社やバイオテクノロジー企業にRNA治療開発への投資を促し、この分野の臨床試験の拡大に貢献しています。特定の遺伝性疾患の治療薬として、ASOをベースとした最初のRNAベースの治療薬がFDAから承認されたことは、RNA治療薬に対する規制当局の支援環境を証明するものです。さらに、RNAベースの治療薬に特化した規制ガイドラインや迅速化されたパスウェイの作成は、この分野のイノベーションを促進するという規制当局のコミットメントを示しています。

デリバリーとターゲティングにおける課題

RNA療法臨床試験市場に影響を与える重大な抑制要因の一つは、RNAベースの治療薬の送達とターゲティングに関連する課題です。RNA分子は本質的に不安定であり、細胞内酵素による分解を受けやすいため、その効力や治療可能性が制限される可能性があります。さらに、RNA治療薬を特定の標的組織や細胞に効果的に送達することが大きな障害となっています。送達システムは、RNA分子を分解から保護し、生物学的障壁を通過し、目的の細胞に効率的に取り込まれるようにする必要があります。さらに、正確なターゲティングを達成することは、オフターゲット効果や潜在的な副作用を避けるために不可欠です。RNA治療薬を目的の作用部位に正確に送達できる安全で効果的な送達手段を開発することは、RNA治療薬の分野では依然として複雑かつ継続的な課題です。Journal of Controlled Release誌に掲載された研究では、ナノ粒子を用いたRNAベースの治療薬の送達の難しさが強調され、安定性と放出制御の問題が明らかになっています。さらに、Nature Reviews Drug Discoveryに掲載された総説では、デリバリーとターゲティングのハードルがRNA治療の臨床応用における重要なボトルネックであり、治療効果や全体的な成功に影響を与えることが強調されています。これらの例は、臨床試験においてRNAベースの治療法の可能性を最大限に引き出すために、デリバリーとターゲティングに関連する課題に取り組むことの重要性を強調しています。

メッセンジャーRNA（mRNA）セグメントは引き続き成長と収益を支配する

RNA療法臨床試験市場のさまざまなモダリティ・セグメントの中で、メッセンジャーRNA（mRNA）セグメントは2023年から2031年の予測期間中に最も高いCAGRを示すと予想され、2022年には最も高い収益を上げました。mRNAベースの治療は、体内の特定のタンパク質を直接コード化するため、ワクチン開発、がん免疫療法、タンパク質代替療法への応用の可能性を提供することから、非常に有望です。mRNAベースのCOVID-19ワクチンの開発成功に見られるように、病原体に対する標的免疫反応を引き起こすmRNAの能力は、その治療可能性を探る臨床試験への大きな関心と投資を促しています。さらに、アンチセンス療法分野もCAGRと収益の両面で大幅な成長を示しています。アンチセンス療法は、特定のRNA分子を標的としてタンパク質の産生を調節することで機能するため、遺伝性疾患やある種のがんの治療に特に適しています。アンチセンス療法の開発は急速に進んでおり、いくつかの臨床試験で様々な疾患に対する潜在的有効性が示されています。RNA干渉（RNAi）分野は、緩やかな成長を遂げつつも、RNA療法臨床試験において不可欠な治療法です。RNAiベースの治療法は特定の遺伝子の発現を阻害し、病気の原因となる遺伝子をターゲットとする有望なアプローチを提供します。最後に、オリゴヌクレオチド、非アンチセンス、非RNAiの分野も着実に成長しており、従来のアンチセンスやRNAiのカテゴリーには当てはまらない革新的なRNAベースの治療法を包含しています。

臨床試験フェーズ別ではフェーズIII試験が市場を独占

RNA療法臨床試験市場において、臨床試験フェーズはRNAベース治療の進行と成功を決定する重要な要素です。様々なフェーズの中で、第III相試験セグメントは2023年から2031年の予測期間中に最も高いCAGRを示すと予想され、2022年に最も高い収益を生み出しました。第III相試験は、より多くの患者を対象とし、既存の標準治療やプラセボと比較してRNA療法の安全性と有効性を評価するように設計されています。フェーズIII試験で良好な結果が得られれば、規制当局の承認が得られ、RNAベースの治療薬が商業化されます。従って、第Ⅲ相臨床試験の高い収益と成長は、製薬会社が後期臨床開発に多額の投資を行っていることに起因しています。さらに、第II相試験もCAGRと収益の両面で大幅な成長を遂げています。第II相試験は、より多くの患者群におけるRNA治療薬の治療効果と投与量を評価するもので、RNA治療薬の第III相試験への移行をサポートする重要なデータを提供します。RNAベースの治療法の臨床開発が進むにつれ、第II相試験の需要が高まり、市場の目覚ましい成長に寄与しています。少人数の健康なボランティアを対象としたRNA治療薬の初期試験を含む第i相試験は、緩やかな成長を見せています。これらの臨床試験は、RNA療法の安全性と投与量の範囲を評価することに重点を置いており、その後の段階への基礎固めにおいて極めて重要な役割を果たしています。最後に、第IV相試験は着実に成長しています。市販後調査試験としても知られる第IV相試験は、実臨床におけるRNA療法の長期的な安全性と有効性を評価するものです。これらの試験は、管理された臨床試験環境を超えて、RNAベースの治療法の性能に関する貴重なデータを提供し、広く使用される間、その安全性と有効性が継続することを保証します。全体として、第III相試験のCAGRと売上は最も高く、RNAベースの治療法の商業化と採用の成功における重要な役割を反映しています。

APACは予測期間中に大きな機会を約束する

北米は突出した市場として浮上し、RNA療法臨床試験で最も高い売上比率を示しました。この地域の市場地位が高いのは、RNAベース療法に多額の投資を行っている大手製薬企業やバイオテクノロジー企業が存在するためです。さらに、確立されたヘルスケアインフラ、支持的な規制環境、慢性疾患の高い有病率が北米のRNA療法臨床試験需要を牽引しています。一方、アジア太平洋地域はRNA療法臨床試験市場において最も高い年間平均成長率（CAGR）を記録しています。この地域の成長は、臨床研究を促進する政府のイニシアチブの増加、ヘルスケア支出の増加、精密医療への注目の高まりなどの要因によるものです。さらに、アジア太平洋地域には大規模で多様な患者集団が存在するため、さまざまな疾患におけるRNAベースの治療法の有効性と安全性を調査する臨床試験の大きなチャンスとなっています。欧州は北米に次ぐ収益を上げており、強固な研究インフラと革新的治療への関心の高まりがRNA療法臨床試験の需要を後押ししています。さらに、中東・アフリカとラテンアメリカ地域も、ヘルスケアインフラの改善と医学研究への投資の増加により、RNA療法臨床試験の緩やかな成長を目の当たりにしています。

主要企業の間で研究開発投資が重要性を増す

RNA療法臨床試験市場は、製薬業界やバイオテクノロジー業界の主要企業間で激しい競争が繰り広げられています。これらの企業は、革新的なRNAベースの治療法を開発し、その安全性と有効性を評価するための臨床試験を実施する最前線にいます。この競合情勢における主要企業には、Moderna Therapeutics、BioNTech SE、Arrowhead Pharmaceuticals、Alnylam Pharmaceuticals、Ionis Pharmaceuticalsなどがあります。これらの企業は、がん、遺伝性疾患、感染症など様々な疾患をターゲットとするRNAベースの治療薬の強力なパイプラインを持ち、RNA治療分野のリーダーとしての地位を確立しています。このような競合環境において、主要企業は自社の地位を強化し、RNA療法臨床試験の進歩を推進するためにいくつかの戦略を採用しています。主要な戦略の1つは、研究開発（R&D）投資に焦点を当てたものです。大手企業は、新規RNAベースの治療法の発見と開発に多大な資源を投入しています。これには、最先端のRNA合成技術や送達技術への投資、RNA分子の安定性や特異性の向上、mRNAやRNA干渉（RNAi）療法などの新しい治療法の探求などが含まれます。さらに、市場プレーヤーは新興市場でも機会を探り、世界の足跡を拡大しようとしています。特にアジア太平洋地域は、患者人口が多く、ヘルスケアへの投資が増加していることから、大きな成長の可能性を秘めています。主要プレーヤーは、革新的なRNAベースの治療に対する需要の高まりを取り込むため、これらの地域でパートナーシップを確立し、臨床試験を実施しています。全体として、RNA療法臨床試験市場の競合動向は、旺盛な研究開発投資、戦略的提携、規制当局との関与、世界展開への注力によって特徴付けられています。同市場の主要企業は、RNA治療分野の発展に尽力し、有望な臨床試験結果を承認され商業的に成功する治療法へと転換させています。臨床試験が進展し、より多くのRNAベースの医薬品が商業化に向かうにつれて、RNA療法臨床試験市場はさらなる成長と変貌を遂げ、広範な疾患に対する個別化治療や標的治療の進歩に貢献するものと期待されます。

市場概要
RNA療法臨床試験市場：モダリティ別 2021-2031
RNA療法臨床試験市場：臨床試験段階別 2021-2031
RNA療法臨床試験市場：治療領域別 2021-2031
RNA療法臨床試験市場：地域別 2021-2031
- 英国と欧州連合
  - 英国
  - ドイツ
  - スペイン
  - イタリア
  - フランス
  - その他欧州地域

第10章アジア太平洋のRNA療法臨床試験市場 2021-2031

市場概要
RNA療法臨床試験市場：モダリティ別 2021-2031
RNA療法臨床試験市場：臨床試験段階別 2021-2031
RNA療法臨床試験市場：治療領域別 2021-2031
RNA療法臨床試験市場：地域別 2021-2031
- アジア太平洋
  - 中国
  - 日本
  - インド
  - オーストラリア
  - 韓国
  - その他アジア太平洋地域

第11章ラテンアメリカのRNA療法臨床試験市場 2021-2031

市場概要
RNA療法臨床試験市場：モダリティ別 2021-2031
RNA療法臨床試験市場：臨床試験段階別 2021-2031
RNA療法臨床試験市場：治療領域別 2021-2031
RNA療法臨床試験市場：地域別 2021-2031
- ラテンアメリカ
  - ブラジル
  - メキシコ
  - その他ラテンアメリカ地域

第12章中東・アフリカのRNA療法臨床試験市場 2021-2031

市場概要
RNA療法臨床試験市場：モダリティ別 2021-2031
RNA療法臨床試験市場：臨床試験段階別 2021-2031
RNA療法臨床試験市場：治療領域別 2021-2031
RNA療法臨床試験市場：地域別 2021-2031
- 中東・アフリカ
  - GCC
  - アフリカ
  - その他中東・アフリカ地域

第13章企業プロファイル

Moderna Therapeutics
BioNTech SE
Arrowhead Pharmaceuticals
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
その他の主要企業

図表

List of Tables

TABLE 1 Global RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 2 Global RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 3 Global RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 4 North America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 5 North America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 6 North America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 7 U.S. RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 8 U.S. RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 9 U.S. RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 10 Canada RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 11 Canada RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 12 Canada RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 13 Rest of North America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 14 Rest of North America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 15 Rest of North America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 16 UK and European Union RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 17 UK and European Union RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 18 UK and European Union RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 19 UK RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 20 UK RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 21 UK RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 22 Germany RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 23 Germany RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 24 Germany RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 25 Spain RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 26 Spain RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 27 Spain RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 28 Italy RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 29 Italy RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 30 Italy RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 31 France RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 32 France RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 33 France RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 34 Rest of Europe RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 35 Rest of Europe RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 36 Rest of Europe RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 37 Asia RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 38 Asia RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 39 Asia RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 40 China RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 41 China RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 42 China RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 43 Japan RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 44 Japan RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 45 Japan RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 46 India RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 47 India RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 48 India RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 49 Australia RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 50 Australia RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 51 Australia RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 52 South Korea RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 53 South Korea RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 54 South Korea RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 55 Latin America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 56 Latin America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 57 Latin America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 58 Brazil RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 59 Brazil RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 60 Brazil RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 61 Mexico RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 62 Mexico RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 63 Mexico RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 64 Rest of Latin America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 65 Rest of Latin America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 66 Rest of Latin America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 67 Middle East and Africa RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 68 Middle East and Africa RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 69 Middle East and Africa RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 70 GCC RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 71 GCC RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 72 GCC RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 73 Africa RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 74 Africa RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 75 Africa RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
TABLE 76 Rest of Middle East and Africa RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
TABLE 77 Rest of Middle East and Africa RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
TABLE 78 Rest of Middle East and Africa RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)

List of Figures

FIG. 1 Global RNA Therapy Clinical Trials Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global RNA Therapy Clinical Trials Market: Quality Assurance
FIG. 5 Global RNA Therapy Clinical Trials Market, By Modality, 2022
FIG. 6 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2022
FIG. 7 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas, 2022
FIG. 8 Global RNA Therapy Clinical Trials Market, By Geography, 2022
FIG. 9 Market Geographical Opportunity Matrix - Global RNA Therapy Clinical Trials Market, 2022

FIG. 10Market Positioning of Key RNA Therapy Clinical Trials Market Players, 2022

FIG. 11Global RNA Therapy Clinical Trials Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

FIG. 12 Global RNA Therapy Clinical Trials Market, By Modality, 2022 Vs 2031, %
FIG. 13 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2022 Vs 2031, %
FIG. 14 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas, 2022 Vs 2031, %
FIG. 15 U.S. RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 16 Canada RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 17 Rest of North America RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 18 UK RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 19 Germany RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 20 Spain RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 21 Italy RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 22 France RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 23 Rest of Europe RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 24 China RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 25 Japan RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 26 India RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 27 Australia RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 28 South Korea RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 29 Rest of Asia RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 30 Brazil RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 31 Mexico RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 32 Rest of Latin America RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 33 GCC RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 34 Africa RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
FIG. 35 Rest of Middle East and Africa RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031

Product Code: 139742-07-23

The RNA therapy clinical trials market is expected to witness a CAGR of 4% during the forecast period of 2023 to 2031, driven by advancements in RNA-based therapeutic approaches and the potential for targeted and personalized treatments. RNA therapy involves the use of ribonucleic acid (RNA) molecules to target specific genes and modulate protein production, offering promising opportunities for treating various diseases, including cancer, genetic disorders, and infectious diseases. The market's revenue is expected to continue its upward trajectory as more RNA-based therapies progress through clinical trials and move toward commercialization. The potential to address previously untreatable diseases and the growing demand for personalized medicine has also contributed to the market's expansion. The ongoing clinical trials in the RNA therapy field are essential for evaluating the safety and efficacy of these innovative therapies. As more clinical data become available, regulatory approvals for RNA-based drugs are likely to increase, paving the way for their wider adoption in clinical practice. In conclusion, the RNA therapy clinical trials market has shown impressive revenue growth and a promising CAGR, driven by the potential of RNA-based therapies to revolutionize disease treatment and offer personalized, targeted approaches to healthcare. As clinical trials progress and more RNA-based drugs enter the market, RNA therapy is poised to have a significant impact on the future of medicine and patient care.

Advancements in RNA Therapeutic Technologies

Advancements in RNA therapeutic technologies have been a major driver behind the growth of the RNA therapy clinical trials market. The development of more stable and efficient delivery systems, such as lipid nanoparticles and viral vectors, has improved the delivery of RNA-based therapies to target tissues and cells. Additionally, innovations in RNA synthesis and modification techniques have enhanced the stability and specificity of RNA molecules, enabling more effective targeting of disease-causing genes. These technological advancements have expanded the potential applications of RNA therapies, leading to a surge in clinical trials exploring their use in treating a wide range of diseases. A study published in Nature Communications reported on the successful delivery of mRNA therapeutics using lipid nanoparticles, showing increased stability and therapeutic efficacy in preclinical models. Another study in the Journal of Controlled Release highlighted the use of self-amplifying mRNA as a vaccine platform, demonstrating robust immune responses against infectious diseases in animal models. These examples demonstrate how technological advancements in RNA therapeutics are driving progress in clinical trials and increasing the potential for successful treatments.

Rising Prevalence of Chronic and Genetic Diseases

The increasing prevalence of chronic and genetic diseases has fueled the demand for innovative and targeted therapies, thus driving the growth of RNA therapy clinical trials. RNA-based therapies offer the potential to address previously untreatable diseases by targeting specific disease-causing genes and modulating protein production. Conditions such as cancer, rare genetic disorders, and neurodegenerative diseases have emerged as key targets for RNA-based therapeutics. The urgency to find effective treatments for these diseases has led to a surge in clinical trials investigating the safety and efficacy of RNA therapies, positioning them as a promising avenue for future medical interventions. The American Cancer Society reported that cancer remains one of the leading causes of death worldwide, leading to significant research and clinical efforts to develop targeted therapies, including RNA-based approaches. Similarly, organizations such as the National Organization for Rare Disorders (NORD) emphasize the need for innovative therapies for rare genetic diseases, driving increased interest and investment in RNA therapy clinical trials.

Supportive Regulatory Environment

The supportive regulatory environment for RNA-based therapies has played a crucial role in driving the growth of the clinical trials market. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established frameworks and expedited pathways to facilitate the development and approval of RNA therapies. These pathways allow for accelerated clinical development and review of promising RNA-based treatments, reducing the time and cost required to bring these therapies to the market. The regulatory support has encouraged more pharmaceutical and biotechnology companies to invest in RNA therapy development and has contributed to the expansion of clinical trials in this field. The FDA's approval of the first RNA-based therapeutic, an ASO-based drug for the treatment of a specific genetic disorder, stands as a testament to the supportive regulatory environment for RNA therapies. Additionally, the creation of regulatory guidelines and expedited pathways specifically tailored for RNA-based therapeutics demonstrates the commitment of regulatory agencies to foster innovation in this field.

Challenges in Delivery and Targeting

One significant restraint impacting the RNA therapy clinical trials market is the challenges associated with the delivery and targeting of RNA-based therapeutics. RNA molecules are inherently unstable and susceptible to degradation by cellular enzymes, which can limit their efficacy and therapeutic potential. Moreover, effectively delivering RNA therapies to specific target tissues and cells poses a significant obstacle. Delivery systems need to protect RNA molecules from degradation, navigate biological barriers, and ensure efficient uptake by the intended cells. Additionally, achieving precise targeting is essential to avoid off-target effects and potential adverse reactions. Developing safe and effective delivery vehicles that can precisely deliver RNA therapies to the desired sites of action remains a complex and ongoing challenge in the field of RNA therapeutics. A study published in the Journal of Controlled Release highlighted the difficulties in delivering RNA-based therapeutics using nanoparticles, where issues of stability and controlled release were identified. Furthermore, a review published in Nature Reviews Drug Discovery emphasized that delivery and targeting hurdles are critical bottlenecks in the clinical translation of RNA therapies, impacting their therapeutic efficacy and overall success. These examples highlight the importance of addressing the challenges associated with delivery and targeting to unlock the full potential of RNA-based therapies in clinical trials.

Messenger RNA (mRNA) Segment to Continue Dominating Growth and Revenues

Among the various modality segments in the RNA therapy clinical trials market, the Messenger RNA (mRNA) segment is expected to exhibit the highest CAGR during the forecast period of 2023 to 2031 and generated the highest revenue in 2022. mRNA-based therapies hold immense promise as they directly encode specific proteins in the body, offering potential applications in vaccine development, cancer immunotherapy, and protein replacement therapies. The ability of mRNA to trigger a targeted immune response against pathogens, such as seen with the successful development of mRNA-based COVID-19 vaccines, has driven significant interest and investment in clinical trials exploring its therapeutic potential. Additionally, the Antisense therapy segment has also shown substantial growth in both CAGR and revenue. Antisense therapies work by targeting specific RNA molecules to modulate protein production, making them particularly suitable for treating genetic disorders and certain types of cancer. The development of Antisense therapies has progressed rapidly, with several clinical trials showcasing their potential efficacy in various diseases. The RNA interference (RNAi) segment, while experiencing moderate growth, remains an essential modality in RNA therapy clinical trials. RNAi-based therapies interfere with the expression of specific genes, offering a promising approach to target disease-causing genes. Lastly, the Oligonucleotide, non-antisense, non-RNAi segment has also witnessed steady growth, encompassing other innovative RNA-based therapeutic modalities that do not fit within the traditional antisense or RNAi categories.

Phase III Trials to Dominate the Market by Clinical Trial Phase

In the RNA therapy clinical trials market, the Clinical Trials Phase is a crucial factor in determining the progression and success of RNA-based therapies. Among the various phases, the Phase III trials segment is expected to exhibit the highest CAGR during the forecast period of 2023 to 2031 and generated the highest revenue in 2022. Phase III trials involve a larger population of patients and are designed to evaluate the safety and efficacy of RNA therapies in comparison to existing standard treatments or placebos. Positive results from Phase III trials are essential for obtaining regulatory approval and commercialization of RNA-based therapies. Consequently, the high revenue and growth in Phase III trials can be attributed to the significant investments made by pharmaceutical companies in late-stage clinical development. Additionally, Phase II trials have also experienced substantial growth in both CAGR and revenue. Phase II trials assess the therapeutic efficacy and dosing of RNA therapies in a larger patient group, providing critical data to support the advancement of RNA therapeutics into Phase III trials. As RNA-based therapies progress through clinical development, the demand for Phase II trials has increased, contributing to their impressive growth in the market. Phase I trials, which involve the initial testing of RNA therapies in a small group of healthy volunteers, have shown moderate growth. These trials focus on evaluating the safety and dosage range of RNA therapies and play a pivotal role in laying the groundwork for subsequent phases. Lastly, Phase IV trials have experienced steady growth. Also known as post-marketing surveillance trials, Phase IV trials assess the long-term safety and effectiveness of RNA therapies in a real-world setting. These trials provide valuable data on the performance of RNA-based therapies beyond the controlled clinical trial environment, ensuring their continued safety and efficacy during widespread use. Overall, Phase III trials stand out with the highest CAGR and revenue, reflecting their critical role in the successful commercialization and adoption of RNA-based therapies.

APAC to Promise Significant Opportunities during the Forecast Period

North America has emerged as a prominent market, showcasing the highest revenue percentage in RNA therapy clinical trials. The region's strong market position can be attributed to the presence of leading pharmaceutical and biotechnology companies with significant investments in RNA-based therapies. Additionally, well-established healthcare infrastructure, a supportive regulatory environment, and a high prevalence of chronic diseases drive the demand for RNA therapy clinical trials in North America. On the other hand, Asia-Pacific has experienced the highest Compound Annual Growth Rate (CAGR) in the RNA therapy clinical trials market. The region's growth can be attributed to factors such as increasing government initiatives to promote clinical research, rising healthcare expenditure, and a growing focus on precision medicine. Moreover, the large and diverse patient population in Asia-Pacific provides a substantial opportunity for clinical trials investigating the efficacy and safety of RNA-based therapies in different disease contexts. Europe follows North America closely in terms of revenue generation, with a robust research infrastructure and growing interest in innovative therapies fueling the demand for RNA therapy clinical trials. Furthermore, the Middle East and Africa, and Latin America regions are also witnessing moderate growth in RNA therapy clinical trials, driven by improving healthcare infrastructure and rising investments in medical research.

R&D Investments to Become Crucial among the Top Market Players

The RNA therapy clinical trials market is witnessing intense competition among top players in the pharmaceutical and biotechnology industries. These companies are at the forefront of developing innovative RNA-based therapies and conducting clinical trials to assess their safety and efficacy. Some of the key players in this competitive landscape include Moderna Therapeutics, BioNTech SE, Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals, among others. These companies have established themselves as leaders in the RNA therapy field, with a strong pipeline of RNA-based therapeutics targeting various diseases, including cancer, genetic disorders, and infectious diseases. In this competitive environment, key players are employing several strategies to strengthen their position and drive advancements in RNA therapy clinical trials. One of the primary strategies is focused on research and development (R&D) investment. Leading companies are dedicating substantial resources to discovering and developing novel RNA-based therapies. This includes investing in cutting-edge RNA synthesis and delivery technologies, enhancing the stability and specificity of RNA molecules, and exploring new therapeutic modalities, such as mRNA and RNA interference (RNAi) therapies. Furthermore, market players are also exploring opportunities in emerging markets to expand their global footprint. Asia-Pacific, in particular, presents significant growth potential, with a large patient population and increasing healthcare investments. Key players are establishing partnerships and conducting clinical trials in these regions to tap into the rising demand for innovative RNA-based therapies. Overall, the competitive trends in the RNA therapy clinical trials market are characterized by robust R&D investments, strategic collaborations, regulatory engagements, and a focus on global expansion. The key players in the market are committed to advancing the field of RNA therapy and translating promising clinical trial results into approved and commercially successful therapies. As clinical trials progress and more RNA-based drugs move towards commercialization, the RNA therapy clinical trials market is expected to witness further growth and transformation, contributing to the advancement of personalized and targeted therapies for a wide range of diseases.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofRNA Therapy Clinical Trials market are as follows:

Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the RNA Therapy Clinical Trials market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Modality

RNA interference
Antisense therapy
Messenger RNA
Oligonucleotide, non-antisense, non-RNAi

Clinical Trials Phase

Phase I
Phase II
Phase III
Phase IV

Therapeutic Areas

Rare Diseases
Anti-infective
Anticancer
Neurological
Alimentary/Metabolic
Musculoskeletal
Cardiovascular Respiratory
Sensory
Others

Region Segment (2021-2031; US$ Million)

North America
- U.S.
- Canada
- Rest of North America

UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe

Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific

Latin America
- Brazil
- Mexico
- Rest of Latin America

Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of RNA Therapy Clinical Trials market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2031.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the RNA Therapy Clinical Trials market?
Which is the largest regional market for RNA Therapy Clinical Trials market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving RNA Therapy Clinical Trials market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the RNA Therapy Clinical Trials market worldwide?

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global RNA Therapy Clinical Trials Market
2.2. Global RNA Therapy Clinical Trials Market, By Modality, 2022 (US$ Million)
2.3. Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2022 (US$ Million)
2.4. Global RNA Therapy Clinical Trials Market, By Therapeutic Areas, 2022 (US$ Million)
2.5. Global RNA Therapy Clinical Trials Market, By Geography, 2022 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2022

3. RNA Therapy Clinical Trials Market: Competitive Analysis

3.1. Market Positioning of Key RNA Therapy Clinical Trials Market Vendors
3.2. Strategies Adopted by RNA Therapy Clinical Trials Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031

4. RNA Therapy Clinical Trials Market: Macro Analysis & Market Dynamics

4.1. Introduction
4.2. Global RNA Therapy Clinical Trials Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)

5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
- 5.3.1. RNA interference
- 5.3.2. Antisense therapy
- 5.3.3. Messenger RNA
- 5.3.4. Oligonucleotide, non-antisense, non-RNAi

6. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)

6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
- 6.3.1. Phase I
- 6.3.2. Phase II
- 6.3.3. Phase III
- 6.3.4. Phase IV

7. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

7.1. Market Overview
7.2. Growth & Revenue Analysis: 2022 Versus 2031
7.3. Market Segmentation
- 7.3.1. Rare Diseases
- 7.3.2. Anti-infective
- 7.3.3. Anticancer
- 7.3.4. Neurological
- 7.3.5. Alimentary/Metabolic
- 7.3.6. Musculoskeletal
- 7.3.7. Cardiovascular Respiratory
- 7.3.8. Sensory
- 7.3.9. Others

8. North America RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

8.1. Market Overview
8.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
8.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
8.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
8.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
- 8.5.1.North America
  - 8.5.1.1. U.S.
    - 8.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 8.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 8.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 8.5.1.2. Canada
    - 8.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 8.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 8.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 8.5.1.3. Rest of North America
    - 8.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 8.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 8.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

9. UK and European Union RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

9.1. Market Overview
9.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
9.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
9.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
9.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
- 9.5.1.UK and European Union
  - 9.5.1.1. UK
    - 9.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 9.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 9.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 9.5.1.2. Germany
    - 9.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 9.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 9.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 9.5.1.3. Spain
    - 9.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 9.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 9.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 9.5.1.4. Italy
    - 9.5.1.4.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 9.5.1.4.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 9.5.1.4.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 9.5.1.5. France
    - 9.5.1.5.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 9.5.1.5.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 9.5.1.5.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 9.5.1.6. Rest of Europe
    - 9.5.1.6.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 9.5.1.6.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 9.5.1.6.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

10. Asia Pacific RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

10.1. Market Overview
10.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
10.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
10.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
10.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
- 10.5.1.Asia Pacific
  - 10.5.1.1. China
    - 10.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 10.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 10.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 10.5.1.2. Japan
    - 10.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 10.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 10.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 10.5.1.3. India
    - 10.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 10.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 10.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 10.5.1.4. Australia
    - 10.5.1.4.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 10.5.1.4.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 10.5.1.4.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 10.5.1.5. South Korea
    - 10.5.1.5.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 10.5.1.5.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 10.5.1.5.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 10.5.1.6. Rest of Asia Pacific
    - 10.5.1.6.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 10.5.1.6.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 10.5.1.6.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

11. Latin America RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

11.1. Market Overview
11.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
11.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
11.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
11.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
- 11.5.1.Latin America
  - 11.5.1.1. Brazil
    - 11.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 11.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 11.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 11.5.1.2. Mexico
    - 11.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 11.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 11.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 11.5.1.3. Rest of Latin America
    - 11.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 11.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 11.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

12. Middle East and Africa RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

12.1. Market Overview
12.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
12.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
12.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
12.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
- 12.5.1.Middle East and Africa
  - 12.5.1.1. GCC
    - 12.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 12.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 12.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 12.5.1.2. Africa
    - 12.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 12.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 12.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  - 12.5.1.3. Rest of Middle East and Africa
    - 12.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
    - 12.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
    - 12.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

13. Company Profile

13.1. Moderna Therapeutics
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
13.2. BioNTech SE
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
13.3. Arrowhead Pharmaceuticals
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
13.4. Alnylam Pharmaceuticals
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
13.5. Ionis Pharmaceuticals
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
13.6. Other Notable Players
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives